TRIUMPH-3 Results: Retatrutide Weight Loss and Cardiovascular Findings Explained
Summary: Eli Lilly announced TRIUMPH-3 topline Phase 3 results on July 23, 2026. In adults with severe obesity and established cardiovascular disease (with or without type 2 diabetes), reported mean weight loss reached 22.6% at the highest studied dose at 80 weeks. Topline data do not establish a demonstrated cardiovascular-outcome benefit — weight loss efficacy and cardiovascular-outcome benefit are different endpoints. Long-term cardiovascular outcomes follow-up continues. Peer-reviewed publication is pending. Retatrutide is not FDA-approved.
Key Facts
Study Population
TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. This population represents a high-risk group where both weight management and cardiovascular risk reduction are clinically important. Estimated enrollment was approximately 10,000 participants.
80-Week Weight Loss Results
Reported mean weight loss reached 22.6% at the highest studied dose at 80 weeks. Eli Lilly's announcement used the efficacy estimand and treatment-regimen estimand — these are different statistical approaches to handling missing data and treatment discontinuation. Full dose-level breakdown and placebo comparison are pending peer-reviewed publication.
What the Cardiovascular Findings Can and Cannot Establish
TRIUMPH-3 topline data report weight loss outcomes in a population with established cardiovascular disease. This is an important population for studying cardiovascular risk. However, topline data do not establish a demonstrated cardiovascular-outcome benefit.
Weight loss efficacy and demonstrated cardiovascular-outcome benefit are different endpoints:
- Weight loss efficacy means the drug produced significant weight reduction in the trial population.
- Cardiovascular-outcome benefit means the drug reduced the rate of major cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo — a separate, longer-term endpoint.
Long-term cardiovascular outcomes follow-up continues. Do not overstate cardiovascular conclusions from topline information.
Topline vs. Peer-Reviewed Evidence
All TRIUMPH-3 data in this article are from Eli Lilly's July 23, 2026 topline announcement. This is a company press release, not a peer-reviewed publication. Full study data, safety profile, secondary endpoints, and cardiovascular outcomes are pending peer-reviewed publication.
Evidence Status
All TRIUMPH-3 data are from Eli Lilly's July 23, 2026 topline announcement. Peer-reviewed publication pending. Cardiovascular-outcome benefit not established from topline data. Retatrutide is not FDA-approved.
Frequently Asked Questions
What were the TRIUMPH-3 results?
TRIUMPH-3 topline results announced July 23, 2026 showed reported mean weight loss of 22.6% at the highest studied dose at 80 weeks in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. These are Eli Lilly topline results; peer-reviewed publication is pending.
Who was in the TRIUMPH-3 trial?
TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. The trial ran for 80 weeks for the primary weight endpoint. Long-term cardiovascular outcomes follow-up continues.
Does TRIUMPH-3 prove retatrutide reduces cardiovascular events?
No. TRIUMPH-3 topline data report weight loss outcomes. Topline data do not establish a demonstrated cardiovascular-outcome benefit. Weight loss efficacy and demonstrated cardiovascular-outcome benefit are different endpoints. Long-term cardiovascular outcomes follow-up continues. Do not overstate cardiovascular conclusions from topline information.
What is the difference between weight-loss efficacy and cardiovascular-outcome benefit?
Weight-loss efficacy means the drug produced significant weight reduction in the trial population. Cardiovascular-outcome benefit means the drug reduced the rate of major cardiovascular events (such as heart attack, stroke, or cardiovascular death) compared to placebo. These require different trial designs and endpoints. TRIUMPH-3 reported weight loss; long-term cardiovascular outcomes are a separate endpoint still being followed.
When will TRIUMPH-3 peer-reviewed results be published?
Peer-reviewed publication of the complete TRIUMPH-3 dataset is pending. Eli Lilly has not announced a specific publication timeline. Results will be submitted to peer-reviewed journals and presented at major medical conferences.